News

Nasdaq

4D Molecular Therapeutics Announces Presentations at ASRS 2025 on Phase 2 Clinical Trials for 4D-150 in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration

4D Molecular Therapeutics is actively presenting interim and 52-week results from their clinical trials at a prominent scientific conference, highlighting their commitment to advancing innovative ...
Business Wire

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from ...
Seeking Alpha

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic ...
The Globe and Mail

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting - Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral ...
Nasdaq

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium ...